Alto Narrows Quarterly Loss, Boosts Capital with $49.9M Private Placement

Ticker: ANRO · Form: 10-Q · Filed: 2025-11-12T00:00:00.000Z

Sentiment: mixed

Topics: Biotechnology, Pharmaceuticals, Clinical Stage, Precision Psychiatry, Net Loss, Capital Raise, R&D Expenses

Related Tickers: ANRO

TL;DR

**Alto's cash burn is still high, but the recent $49.9M private placement is a lifeline that buys them more time to hit clinical milestones.**

AI Summary

Alto Neuroscience, Inc. (ANRO) reported a net loss of $14.181 million for the three months ended September 30, 2025, an improvement from the $16.783 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss increased slightly to $47.056 million from $46.230 million in the prior year. Research and development expenses decreased to $10.525 million for the quarter, down from $13.060 million year-over-year, and to $33.623 million for the nine-month period, down from $36.196 million. General and administrative expenses also saw a quarterly decrease to $4.426 million from $5.826 million. The company's cash and cash equivalents decreased to $137.816 million as of September 30, 2025, from $168.229 million at December 31, 2024. Alto completed a private placement transaction on October 21, 2025, raising net proceeds of $49.9 million through the issuance of 3,832,263 shares of common stock and pre-funded warrants for 4,622,251 shares. The accumulated deficit reached approximately $185.5 million by September 30, 2025, highlighting the need for additional capital to fund operations and product development.

Why It Matters

Alto Neuroscience's ability to reduce its quarterly net loss and R&D expenses, while securing a significant $49.9 million in new capital post-quarter, is a critical signal for investors. This fresh funding extends its cash runway, crucial for a clinical-stage biopharmaceutical company with an accumulated deficit of $185.5 million. For employees, continued funding means job security and progress on their seven clinical-stage assets. Customers and the broader market benefit from the potential development of personalized treatments for MDD, BPD, TRD, and schizophrenia, offering hope in highly competitive therapeutic areas. The capital infusion also strengthens Alto's position against competitors in the precision psychiatry space.

Risk Assessment

Risk Level: medium — Alto Neuroscience has an accumulated deficit of approximately $185.5 million as of September 30, 2025, and continues to incur significant operating losses, with a net loss of $47.056 million for the nine months ended September 30, 2025. While the recent $49.9 million private placement provides a capital boost, the company explicitly states it will need to raise additional capital to fund operations until profitability, indicating ongoing financial risk.

Analyst Insight

Investors should monitor Alto's progress on its clinical pipeline and the utilization of the recently raised $49.9 million. Given the high accumulated deficit and continued losses, new investments should be considered speculative, focusing on the potential for successful clinical trial outcomes and future product commercialization.

Financial Highlights

debt To Equity
0.32
revenue
N/A
operating Margin
N/A
total Assets
$147.006M
total Debt
$26.277M
net Income
-$14.181M
eps
-$0.52
gross Margin
N/A
cash Position
$137.816M
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What were Alto Neuroscience's net losses for Q3 2025 and the nine months ended September 30, 2025?

Alto Neuroscience reported a net loss of $14.181 million for the three months ended September 30, 2025. For the nine months ended September 30, 2025, the net loss was $47.056 million.

How much cash and cash equivalents did Alto Neuroscience have as of September 30, 2025?

As of September 30, 2025, Alto Neuroscience had $137.816 million in cash and cash equivalents, a decrease from $168.229 million at December 31, 2024.

Did Alto Neuroscience raise additional capital after September 30, 2025?

Yes, on October 21, 2025, Alto Neuroscience completed a private placement transaction, raising net proceeds of $49.9 million.

What is Alto Neuroscience's accumulated deficit as of September 30, 2025?

Alto Neuroscience's accumulated deficit as of September 30, 2025, was approximately $185.5 million, reflecting significant historical operating losses.

How did Alto Neuroscience's research and development expenses change in Q3 2025?

Research and development expenses for Alto Neuroscience decreased to $10.525 million for the three months ended September 30, 2025, down from $13.060 million in the same period of 2024.

What is Alto Neuroscience's primary business focus?

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized treatment options for high-need therapeutic areas like major depressive disorder (MDD), bipolar depression (BPD), treatment resistant depression (TRD), and schizophrenia.

What are the key risks for investors in Alto Neuroscience?

Key risks include the company's significant accumulated deficit of $185.5 million, ongoing operating losses, and the need to raise additional capital to fund operations until profitability, which is not assured.

How many shares of common stock were outstanding for Alto Neuroscience as of November 7, 2025?

As of November 7, 2025, the number of shares of Alto Neuroscience's Common Stock outstanding was 31,066,335.

What was the impact of the initial public offering (IPO) on Alto Neuroscience's capital?

Alto Neuroscience completed its IPO in February 2024, issuing 9,246,000 shares of common stock and receiving net proceeds of $133.0 million after deducting offering costs.

What is the significance of Alto Neuroscience's Precision Psychiatry Platform?

The Precision Psychiatry Platform is proprietary and scalable, aiming to discover brain-based biomarkers to better identify which patients are more likely to respond to Alto's novel product candidates, thereby personalizing treatment options.

Risk Factors

Industry Context

Alto Neuroscience operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on developing novel treatments for neurological and psychiatric disorders. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success hinges on innovation, clinical trial outcomes, and securing substantial funding to navigate these challenges.

Regulatory Implications

The company's product development pipeline is subject to stringent regulatory oversight from bodies like the FDA. Successful navigation of the approval process is critical for market entry. Any delays or failures in regulatory submissions or approvals represent a significant risk to the company's future prospects and financial health.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]

Key Dates

Glossary

Accumulated Deficit
The total net losses of a company since its inception, minus any net gains. It represents the cumulative losses that have not been offset by profits. (Alto Neuroscience has an accumulated deficit of $185.5 million as of September 30, 2025, indicating that the company has historically spent more than it has earned, highlighting its need for ongoing funding.)
Operating Right-of-Use Asset
An asset recognized under accounting standards (like ASC 842) representing a lessee's right to use an identified asset for a specified period, typically related to leases. (This asset, valued at $4.459 million as of September 30, 2025, reflects the company's use of leased assets, such as office or lab space.)
Pre-funded Warrants
A type of warrant that allows the holder to purchase shares at a nominal exercise price, effectively acting as a substitute for purchasing shares directly in a private placement. (These were issued as part of the October 21, 2025, private placement, indicating a financing structure designed to provide immediate capital while potentially deferring full equity dilution.)
Weighted-average number of common shares outstanding
The average number of a company's shares that have been outstanding during a specific period, used for calculating earnings per share (EPS). (This metric is crucial for understanding the EPS of $ (0.52) for Q3 2025, as it accounts for changes in share count during the period.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, Alto Neuroscience has seen a reduction in its net loss for the third quarter of 2025 ($14.181M vs. $16.783M), driven by decreased operating expenses, particularly in research and development ($10.525M vs. $13.060M). However, the net loss for the nine-month period has slightly increased ($47.056M vs. $46.230M). Cash reserves have declined to $137.816M from $168.229M at year-end 2024, underscoring the ongoing need for capital. No new significant risks were explicitly detailed in the provided excerpts, but the existing risks related to funding and product development remain paramount.

Filing Stats: 4,671 words · 19 min read · ~16 pages · Grade level 19.5 · Accepted 2025-11-12 08:32:05

Key Financial Figures

Filing Documents

- Financial Information

Part I - Financial Information

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) F- 1

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 23

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 39

Controls and Procedures

Item 4. Controls and Procedures 39

- Other Information

Part II - Other Information

Legal Proceedings

Item 1. Legal Proceedings 40

Risk Factors

Item 1A. Risk Factors 40

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 40

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 41

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 41

Other Information

Item 5. Other Information 41

Exhibits

Item 6. Exhibits 42

Signatures

Signatures 43 Unless context otherwise requires, the terms the "Company," "Alto," "we," "us," "our," and similar references in this Quarterly Report on Form 10-Q refer to Alto Neuroscience, Inc. and its consolidated subsidiary. Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this Quarterly Report, including statements regarding our plans, objectives, goals, strategies, future events, future revenues or performance, financing needs, plans, or intentions relating to product candidates and markets and business trends are forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "can," "contemplate," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "objective," "plan," "potential," "predict," "project," "shall," "should," "target," "will," or "would," or the negative of these words or other similar terms or expressions. These statements involve known and unknown risks, uncertainties, and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress, and results of our research and development programs, preclinical studies, any clinical trials, and investigational new drug, or IND, and other regulatory submissions; the ability of our approach to reproducibly predict treatment outcomes for product candidates amongst identified pati

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited). Alto Neuroscience, Inc. and Subsidiary Condensed Consolidated Balance Sheets (Unaudited) (in thousands, except per share amounts) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 137,816 $ 168,229 Prepaid expenses and other current assets 1,632 1,108 Total current assets 139,448 169,337 Restricted cash 500 500 Property and equipment, net 2,029 2,666 Operating right-of-use asset 4,459 5,035 Other assets 570 4 Total assets $ 147,006 $ 177,542 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 2,059 $ 1,579 Accrued expenses and other current liabilities 6,986 8,429 Total current liabilities 9,045 10,008 Term loan, non-current 20,314 10,254 Convertible Grant Agreement 2,124 1,304 Lease liability, long-term 3,966 4,516 Total liabilities 35,449 26,082 Commitments and contingencies (Note 11) Stockholders' equity: Common stock (par value $ 0.0001 ), 500,000 shares authorized; 27,168 and 26,987 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 3 3 Additional paid-in capital 296,992 289,954 Accumulated deficit ( 185,452 ) ( 138,396 ) Accumulated other comprehensive income (loss) 14 ( 101 ) Total stockholders' equity 111,557 151,460 Total liabilities and stockholders' equity $ 147,006 $ 177,542 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. F-1 Table of Contents Alto Neuroscience, Inc. and Subsidiary Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except per share amounts) Three months ended September 30, Nine months ended September 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 10,525 $ 13,060 $ 33,623 $ 36,196 General and administrative 4,426 5,826 15,686 15,417 Total operating expenses 14,951 18,886 49,309 51,613 Loss from operations ( 14,9

View on Read The Filing